U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Method (Laboratory Tests, Imaging Tests), By End-use (Hospitals, Clinics, Diagnostic Laboratories), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Diagnostic Method
  • 1.2.2. End-use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Diagnostic Method Outlook
  • 2.2.2. End-use Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of target disease
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Growing awareness and screening initiatives
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory hurdles and compliance requirements
    • 3.2.2.2. Underdiagnosis and misdiagnosis
• 3.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Regulatory Scenario
• 3.5. Reimbursement Scenario
• 3.6. Pricing Analysis
• 3.7. Target Population Analysis

Chapter 4. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Estimates & Trend Analysis

• 4.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Segment Dashboard
• 4.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: Diagnostic Method Movement Analysis
• 4.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by Diagnostic Method, 2018 to 2030 (USD Million)
• 4.4. Laboratory Tests
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Indirect Pancreatic Function Tests
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Stool Tests
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Blood Tests
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Other Tests
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Imaging Tests
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. CT Scans
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. MRI
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Endoscopic Ultrasound for Pancreatic Function Tests
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Estimates & Trend Analysis

• 5.1. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Segment Dashboard
• 5.2. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market: End-use Movement Analysis
• 5.3. U.S. Exocrine Pancreatic Insufficiency Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Hospitals & Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diagnostic Laboratories
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Research Institutes
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Categorization
• 6.2. Participant Overview
• 6.3. Financial Performance
• 6.4. Product Benchmarking
• 6.5. Heat Map Analysis
• 6.6. Vendor Landscape
  • 6.6.1. List of key distributors and channel partners
  • 6.6.2. Consumer behavior analysis
  • 6.6.3. ChiRhoClin
    • 6.6.3.1. Company overview
    • 6.6.3.2. Financial performance
    • 6.6.3.3. Product benchmarking
    • 6.6.3.4. Strategic initiatives
  • 6.6.4. Certest Biotec.
    • 6.6.4.1. Company overview
    • 6.6.4.2. Financial performance
    • 6.6.4.3. Product benchmarking
    • 6.6.4.4. Strategic initiatives
  • 6.6.5. ScheBo Biotech AG
    • 6.6.5.1. Company overview
    • 6.6.5.2. Financial performance
    • 6.6.5.3. Product benchmarking
    • 6.6.5.4. Strategic initiatives
  • 6.6.6. Immundiagnostik AG
    • 6.6.6.1. Company overview
    • 6.6.6.2. Financial performance
    • 6.6.6.3. Product benchmarking
    • 6.6.6.4. Strategic initiatives
  • 6.6.7. Laboratory Corporation of America Holdings
    • 6.6.7.1. Company overview
    • 6.6.7.2. Financial performance
    • 6.6.7.3. Product benchmarking
    • 6.6.7.4. Strategic initiatives
  • 6.6.8. Boster Biological Technology
    • 6.6.8.1. Company overview
    • 6.6.8.2. Financial performance
    • 6.6.8.3. Product benchmarking
    • 6.6.8.4. Strategic initiatives
  • 6.6.9. ALPCO Diagnostics
    • 6.6.9.1. Company overview
    • 6.6.9.2. Financial performance
    • 6.6.9.3. Product benchmarking
    • 6.6.9.4. Strategic initiatives
  • 6.6.10. Quest Diagnostics Incorporated
    • 6.6.10.1. Company overview
    • 6.6.10.2. Financial performance
    • 6.6.10.3. Product benchmarking
    • 6.6.10.4. Strategic initiatives
  • 6.6.11. DiaSorin S.p.A.
    • 6.6.11.1. Company overview
    • 6.6.11.2. Financial performance
    • 6.6.11.3. Product benchmarking
    • 6.6.11.4. Strategic initiatives
  • 6.6.12. ARUP Laboratories
    • 6.6.12.1. Company overview
    • 6.6.12.2. Financial performance
    • 6.6.12.3. Product benchmarking
    • 6.6.12.4. Strategic initiatives
  • 6.6.13. Alpha Laboratories
    • 6.6.13.1. Company overview
    • 6.6.13.2. Financial performance
    • 6.6.13.3. Product benchmarking
    • 6.6.13.4. Strategic initiatives
  • 6.6.14. Verisana Laboratories
    • 6.6.14.1. Company overview
    • 6.6.14.2. Financial performance
    • 6.6.14.3. Product benchmarking
    • 6.6.14.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 U.S. Exocrine Pancreatic Insufficiency Diagnostics market revenue estimates and forecast, by Diagnostic Method, 2018 - 2030 (USD Million)
• Table 4 U.S. exocrine pancreatic insufficiency diagnostics market revenue estimates and forecast, by end-use, 2018 - 2030 (USD Million)
• Table 5 Laboratory information U.S.
• Table 6 List of players adopting merger & acquisition strategy
• Table 7 List of players adopting acquisition strategy
• Table 8 List of players adopting other strategy

List of Figures

• Fig. 1 U.S. exocrine pancreatic insufficiency diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 QFD modelling for market share assessment.
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Diagnostic method and end-use segment snapshot
• Fig. 10 Competitive landscape snapshot
• Fig. 11 Market dynamics
• Fig. 12 Porter's five forces analysis
• Fig. 13 PESTLE analysis
• Fig. 14 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method outlook and key takeaways
• Fig. 15 U.S. Exocrine Pancreatic Insufficiency Diagnostics market: Diagnostic Method movement analysis
• Fig. 16 Laboratory Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Laboratory Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 18 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Indirect Pancreatic Function Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 20 Stool Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Stool Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 22 Blood Tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Blood Tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 24 Other tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Other tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 26 Imaging tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Imaging tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 28 CT scans market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 CT scans market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 30 MRI market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Endoscopic ultrasound for pancreatic function tests for pancreatic function tests market estimates and forecast, 2018 - 2030 (Number of Tests, '000)
• Fig. 33 U.S. exocrine pancreatic insufficiency diagnostics market: By end-use, key takeaways
• Fig. 34 U.S. exocrine pancreatic insufficiency diagnostics market, by end-use: Market share, 2023 & 2030
• Fig. 35 Hospitals and clinics market, 2018 - 2030 (USD Million)
• Fig. 36 Diagnostic laboratories market, 2018 - 2030 (USD Million)
• Fig. 37 Research institutes market, 2018 - 2030 (USD Million)
• Fig. 38 Research institutes market, 2018 - 2030 (Number of Tests, '000)
• Fig. 39 Company/competition categorization
• Fig. 40 Heat map analysis
• Fig. 41 Consumer behavior analysis
• Fig. 42 Exocrine pancreatic insufficiency diagnostics industry key takeaways
• Fig. 43 Strategy mapping